News Archive

The Maryland Stem Cell Research Commission (Commission) approved funding for 29 awards for a total of $8,533,987. These awards will be distributed between 6 different research institutes and 6 companies and will address over 20 different diseases and conditions. “The high level of work that our stem cell researchers and companies are performing is a testament to Maryland’s status as a national leader in the life sciences industry,” said Governor Larry Hogan. “Our administration’s commitment to this and other lifesaving therapies is in line with the Commission’s work to accelerate the path to develop cures for all.”

Immunomic Therapeutics negotiated an exclusive license to Annias Immunotherapeutics’ platform covering technology for targeting cytomegalovirus (CMV) antigens in cancer. The CMV immunotherapy platform was developed by John H. Sampson, M.D., Ph.D., and Duane A. Mitchell, M.D., Ph.D., at Duke University and licensed to Annias. Immunomic will combine the CMV platform with its own nucleic acid-based immunotherapy LAMP-Vax™ technology as a potential treatment for cancers that express CMV, including glioblastoma multiforme (GBM). Financial details of the licensing agreement were not disclosed

US venture capital fund of funds Greenspring has hit $595m for its latest flagship fundraise, AltAssets can reveal.

The firm has registered the amount for Greenspring Global Partners VIII across a string of affiliated vehicles according to filings made with the US securities regulator.

The Healthcare Businesswomen’s Association (HBA) announced that its 2017 Woman of the Year is Bahija Jallal, PhD, executive vice president, AstraZeneca, and head of MedImmune. MedImmune is the global biologics research and development arm of AstraZeneca.

Yes, we’re still going to have networking with a few drinks and snacks as usual!

Join us on May 18th in the back lot at Johns Hopkins Montgomery County campus to explore local biotech careers w/ Employers who have open jobs, and two great workforce training organizations that can help you advance your career – Worksource Montgomery & BioTrain. As an added bonus you get to explore the brand new Mobile Exploration Lab (MXLab).

Even if you’re happy with your current position and aren’t looking for something new. Spend some time with your peers and friends to network along with seeing what these organizations have to offer.

Come by for the whole event or just a part of it. We’re looking forward to seeing you there!

The Inova Health System and the University of Virginia announced today that they have awarded $450,000 to nine UVA-Inova joint research teams for projects focused on how to better predict, prevent and treat disease. In the fall of 2016, Inova and UVA announced a comprehensive research and education partnership to accelerate joint discovery and the application of translational medical research.  The seed grant awards mark the first of many joint research collaborations. UVA’s Translational Health Research Institute of Virginia, which facilitates translational health research across UVA, and Inova’s Translational Medicine Institute, are helping support these research projects.

Five proposals submitted this spring to Johns Hopkins’ Idea Lab crowdsourcing website will receive funding by virtue of garnering the most support in online voting.

Funding will be awarded to a health care innovation conference that expands upon the popular MedHacks event, a science-themed summer camp for Baltimore fifth-graders, and a place for students to get free food left over from events, among other creative concepts.

The Big Idea CONNECTpreneur Summer Forum Tysons Corner – June 13, 2017

“The Best Networking Event in the MidAtlantic.”

This will be our 24th consecutive SOLD OUT event over the last 6 years!

Over 70% of previous attendees surveyed say that CONNECTpreneur is the “Number One” tech and investor event in the Mid-Atlantic region!

DCInno calls CONNECTpreneur “The Best Networking Event in DC” and a “NETWORKING JACKPOT” of the Region’s TOP Entrepreneurs, Business Leaders, CXOs, Angels, and VCs.

This UNIQUE EVENT is like NONE OTHER in our region, because of the high quality of our attendees, speakers and presenters.

And YES, the networking is unprecedented!

Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. 

Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage drug-development programs.